Related Experiment Video
Updated: Jul 4, 2026
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Repurposing T‑614 for Gout: An In Silico Framework Integrating Network Pharmacology, Mendelian Randomization, and
Huiqiong Zeng1, Songqing Lin2, Zebin Liu3
1Department of Rheumatology, Women and Children Health Institute of Futian, Shenzhen 518000, China.
ACS Omega
|July 3, 2026
Summary
This study explores T-614 (iguratimod) as a potential gout treatment by analyzing its molecular mechanisms and genetic links to immune cells. Findings suggest T-614 may target key inflammatory pathways, supporting its therapeutic potential for gout.
Area of Science:
- Computational drug discovery
- Immunology
- Pharmacology
Background:
- Gout, an inflammatory arthritis, requires better therapies.
- T-614 (iguratimod), an immunomodulator, shows promise for gout but its mechanisms are unclear.
Purpose of the Study:
- To investigate the molecular and immunogenetic mechanisms of T-614 in gout using an integrative in silico approach.
- To identify potential drug targets and causal immunophenotypes for gout treatment.
Main Methods:
- Assessed T-614 druggability and pharmacokinetics (SwissADME, ADMET Lab 2.0).
- Employed network pharmacology and protein-protein interaction analysis.
- Conducted two-sample Mendelian randomization (MR) analysis for immune-cell traits and gout.
- Performed molecular docking, dynamics simulations, and MM/GBSA calculations for AKT1.
- Analyzed single-cell RNA sequencing (scRNA-seq) data.
Main Results:
- T-614 exhibits favorable drug-likeness and high plasma protein binding.
- Network analysis identified AKT1, TNF, and IL1B as key targets in relevant signaling pathways.
- Molecular simulations supported a stable AKT1/T-614 complex.
- MR identified 29 immune-cell traits linked to gout, highlighting CD16+ monocytes and CD25+ Tregs.
- scRNA-seq confirmed target gene expression in these immune subsets.
Conclusions:
- This in silico study suggests T-614 can engage multiple gout-related immunomodulatory targets.
- The findings generate genetically and cell-type-informed hypotheses for T-614's efficacy in gout.
- Further biochemical, cellular, and in vivo validation is warranted.
